
Cybin (CYBN) Stock Forecast & Price Target
Cybin (CYBN) Analyst Ratings
Bulls say
Cybin Inc is experiencing accelerated commercial readiness efforts across its therapeutic programs, positioning the company favorably for future launches in the interventional psychiatry space. With a strong foundation in clinical execution, commercial groundwork, and enhanced financial stability, Cybin is well-prepared for two major data readouts anticipated in 2026. Furthermore, the successful completion of the Phase 2 CYB004 generalized anxiety disorder trial and continued advancements in the Phase 3 CYB003 major depressive disorder program highlight the company's ongoing progress and commitment to developing effective mental health treatments.
Bears say
Cybin Inc. faces a negative outlook due to multiple fundamental challenges, including the complexities involved in developing neuropsychiatric products, which have high risks of clinical trial failures and unproven safety and efficacy of its psychedelic compounds. The company's recent dilution from capital-raising efforts has negatively impacted its discounted cash flow (DCF) valuation, causing a significant decrease in the projected price target. Furthermore, uncertainties regarding regulatory approval, intellectual property protection, and market acceptance of psychedelic therapies heighten the risk profile, making the commercial viability of Cybin's products uncertain.
This aggregate rating is based on analysts' research of Cybin and is not a guaranteed prediction by Public.com or investment advice.
Cybin (CYBN) Analyst Forecast & Price Prediction
Start investing in Cybin (CYBN)
Order type
Buy in
Order amount
Est. shares
0 shares